Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease

Antimisiaris, Sophia G.; Mourtas, Spyridon; Markoutsa, Eleni; Σκούρας, Αθανάσιος; Papadia, Konstantina

doi:10.1002/9781118774205.ch4

Cited by 7 publications

(13 citation statements)

References 328 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A C C E P T E D M A N U S C R I P T 4 aggregates) (Antimisiaris et al 2014). Between the latter, liposomes with a lipid derivative of curcumin (TREG) immobilized on their surface were reported to have very high affinity for Aβ deposits (Mourtas et al, 2011) and demonstrated a strong inhibitory action towards Aβ peptide aggregation (Taylor et al, 2011).…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…The strategy of utilizing nanoparticulate systems decorated with more than one targeting ligands in order to enhance NP delivery to specific targets, has been successfully explored in several studies (Kibria et al 2011;Kluza et al 2012;Li et al 2012;Bae et al 2012;Gao et al 2012), and some types of NPs have been evaluated as theranostic carriers for Alzheimer's disease (AD) (Antimisiaris, 2014;Antimisiaris et al 2014;Ma et al 2015;Mourtas et al 2014). The classic neuropathological signs of Alzheimer's disease are amyloid deposits and neurofibrillary tangles, which consist of the protein fragment betaamyloid (Aβ-peptides) and tau (a protein normally involved in maintaining the internal structure of the nerve cell), respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice

Papadia

Giannou

Markoutsa

et al. 2017

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Multifunctional liposomes (mf-LIPs) having a curcumin-lipid ligand (to target amyloids) together with two ligands to target the transferrin, and the low-density apolipoprotein receptor of the blood-brain-barrier (BBB) on their surface, were previously studied (in vitro) as potential theranostic systems for Alzheimer's disease (AD) (Papadia et al., 2017, Eur. J. Pharm. Sciences; 101:140-148). Herein, the targeting potential of mf-LIPs was compared to that of BBB-LIPs (liposomes having only the two BBB-specific ligands) in FVB mice (normal), as well as in double transgenic mice (APP/PS1) and their corresponding littermates (WT), by live-animal (in vivo) and explanted organ (ex vivo) imaging. In FVB mice, the head-signals of mf-LIPs and BBB-LIPs are either similar, or signals from mf-LIP are higher, suggesting that the co-presence of the curcumin derivative on the liposome surface does not disturb the functionality of the BBB-specific ligands. Higher brain/liver+spleen ratios (ex vivo) were calculated post-injection of mf-LIP, compared to those found after BBB-LIP injection, due to the reduced distribution of mf-LIPs in the liver and spleen; showing that the curcumin ligand increases the stealth properties of liposomes by reducing their uptake by liver and spleen. The later effect is more pronounced when the density of the BBB-specific ligands on the mf-LIPs is 0.1mol%, compared to 0.2%, highlighting the importance of this parameter. When a high lipid dose (4mg/mouse) is injected in WT and APP/PS1 mice, the head-signals of mf-LIPs are significantly higher than those of BBB-LIPs, but no differences are observed between WT and APP/PS1 mice. However, after administration of a low liposome dose (0.05mg/mouse) of mf-LIPs, significant differences in the head-signals are found between WT and transgenic mice, highlighting the AD theranostic potential of the multifunctional liposomes, as well as the importance of the experimental parameters used in such in vivo screening studies.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice

Papadia

Giannou

Markoutsa

et al. 2017

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…This increase can be attributed to specific functionalities within the nanocarrier that make them have better ability to cross the BBB than the drug on its own. Moreover, nanocarriers have been proposed for theranosis delivering both imaging and therapeutic agents simultaneously (23) . That way, nanocarriers can be modified with targeting moieties to bind preferentially putative receptors or transporters expressed at the BBB,…”

Section: Drug Delivery Strategies For Admentioning

confidence: 99%

“…Therefore, other drug delivery strategies such as extended release, orally disintegrating, sublingual, intranasal, intramuscular, transdermal forms and NTDDS are being researched in the hope to improve the patient compliance and assist caretaker in the process of patient caring.  Good stability, biocompatibility, biodegradability, with low toxicity and immunogenic response (96)  Sustained drug release  Chitosan NPs can be easily produced by ionic gelation method with a considerably low cost (35) .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen

El-Salamouni

El-Refaie

et al. 2017

Journal of Controlled Release

171

View full text Add to dashboard Cite

“…Furthermore, a tenacious potential and biocompatibility of nanomaterials assist in the development of these nanomedicines (Dvir et al, 2011;Lozano et al, 2012a,b;Escamilla-Rivera et al, 2016). Interestingly, they show a high surface-to-volume ratio which indicates that one can easily modify its surface for better drug loading and targeting (Antimisiaris et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Nanomedicines: Challenges and perspectives for future nanotechnology in the healthcare system

AJAZUDDIN¹,

Siddique²,

Alexander³

et al. 2019

Sci. Res. Essays

View full text Add to dashboard Cite

A novel approach of combining nanotechnology to the pharmaceutical and biotechnological field resulted in the formation of nanomedicines. Nanomedicines have progressed to a more considerable extent for curing irremediable diseases such as neurological defects, cardiovascular defects, etc., because of its minute size which assists in increased surface area and hence a remarkable dissolution profile. In addition to the health care sector, modernization of nanotechnology has also been implemented in other industries like cosmetics, electronics, catalysis, and chemical industries. Nanoparticles can be made by using polymers, either lipids or inorganic compounds like metals. They can be prepared by using either top to bottom or bottom to top approach. Interestingly, polymeric nanoparticles have provided an enormous opportunity to alter the surface of the nanoparticles leading to better drug delivery and drug targeting. However, these have the potential to induce toxicity as well. Also, the toxicity profile still has to be investigated. Moreover, characterization of the nanomedicines is always trouble, which has created a gap between conventional drugs and nanomedicines.

show abstract

Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease

Cited by 7 publications

References 328 publications

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice

Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Nanomedicines: Challenges and perspectives for future nanotechnology in the healthcare system

Contact Info

Product

Resources

About